Candriam Equities L Biotech.C-H EUR Acc/  LU1120766206  /

Fonds
NAV6/18/2024 Chg.-2.1000 Type of yield Investment Focus Investment company
196.1800EUR -1.06% reinvestment Equity Worldwide Candriam 

Investment strategy

The fund seeks to achieve capital growth by investing in the principal assets traded and to outperform the benchmark. Equities of companies active in biotechnology whose registered offices and/or principal activities are throughout the world. The management team makes discretionary investment choices based on economic/financial analyses. There are two strands in the selection of companies: a clinical analysis and a fundamental analysis. The clinical analysis aims to assess the quality of the available clinical data and to use only companies found to be convincing in this respect. The fundamental analysis selects the best companies according to five criteria: quality of management, growth potential, competitive advantage, value creation and indebtedness. The fund promotes, among other characteristics, environmental and/or social characteristics but does not have sustainable investment as its objective. The analysis of ESG aspects (environment, social, governance) is included in the selection, analysis and global evaluation of companies. The fund is managed actively and the investment approach implies a reference to a benchmark (the index). The index measures the performance of NASDAQ-listed companies from the biotechnology and pharmaceuticals sector
 

Investment goal

The fund seeks to achieve capital growth by investing in the principal assets traded and to outperform the benchmark.
 

Master data

Type of yield: reinvestment
Funds Category: Equity
Region: Worldwide
Branch: Sector Biotechnology
Benchmark: Nasdaq Biotechnology Index (Net Return)
Business year start: 1/1
Last Distribution: -
Depository bank: CACEIS Bank, Luxembourg Branch
Fund domicile: Luxembourg
Distribution permission: Austria, Germany, Switzerland
Fund manager: Rudi Van Den Eynde
Fund volume: 1.49 bill.  USD
Launch date: 1/22/2015
Investment focus: -

Conditions

Issue surcharge: 3.50%
Max. Administration Fee: 1.60%
Minimum investment: 0.00 EUR
Deposit fees: -
Redemption charge: 0.00%
Key Investor Information: Download (Print version)
 

Investment company

Funds company: Candriam
Address: 19-21 route d'Arlon, 8009, Strassen
Country: Luxembourg
Internet: www.candriam.com
 

Assets

Stocks
 
98.22%
Cash
 
1.75%
Others
 
0.03%

Countries

United States of America
 
74.39%
United Kingdom
 
5.61%
Denmark
 
3.97%
Netherlands
 
2.96%
France
 
2.64%
Cayman Islands
 
2.23%
Ireland
 
1.90%
Cash
 
1.75%
Canada
 
1.56%
Belgium
 
1.11%
Germany
 
0.98%
Virgin Islands (British)
 
0.27%
China
 
0.23%
Others
 
0.40%

Branches

Pharma/Biotechnology
 
96.42%
Cash
 
1.75%
Healthcare services
 
1.15%
Gesundheitswesen/ Informationstechnologie
 
0.30%
Others
 
0.38%